Integrative physiology of pneumonia
LJ Quinton, AJ Walkey, JP Mizgerd - Physiological reviews, 2018 - journals.physiology.org
Pneumonia is a type of acute lower respiratory infection that is common and severe. The
outcome of lower respiratory infection is determined by the degrees to which immunity is …
outcome of lower respiratory infection is determined by the degrees to which immunity is …
Cannabinoid receptor type 2: a possible target in SARS-CoV-2 (CoV-19) infection?
F Rossi, C Tortora, M Argenziano, A Di Paola… - International Journal of …, 2020 - mdpi.com
In late December 2019, a novel coronavirus (SARS-CoV-2 or CoV-19) appeared in Wuhan,
China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract …
China, causing a global pandemic. SARS-CoV-2 causes mild to severe respiratory tract …
[HTML][HTML] Mesenchymal stem cells and management of COVID-19 pneumonia
SM Metcalfe - Medicine in drug discovery, 2020 - Elsevier
Abstract Human coronavirus, hCoV-19, is highly pathogenic with severe pneumonia
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …
associated with rapid virus replication. Arising in Wuhan China December 2019, the current …
Nrf2 Activator PB125® as a Potential Therapeutic Agent against COVID-19
JM McCord, BM Hybertson, A Cota-Gomez, KP Geraci… - Antioxidants, 2020 - mdpi.com
Nrf2 is a transcription factor that regulates cellular redox balance and the expression of a
wide array of genes involved in immunity and inflammation, including antiviral actions. Nrf2 …
wide array of genes involved in immunity and inflammation, including antiviral actions. Nrf2 …
Genome-wide association study identifies human genetic variants associated with fatal outcome from Lassa fever
Infection with Lassa virus (LASV) can cause Lassa fever, a haemorrhagic illness with an
estimated fatality rate of 29.7%, but causes no or mild symptoms in many individuals. Here …
estimated fatality rate of 29.7%, but causes no or mild symptoms in many individuals. Here …
The emerging role of leukemia inhibitory factor in cancer and therapy
Leukemia inhibitory factor (LIF) is a multi-functional cytokine of the interleukin-6 (IL-6)
superfamily. Initially identified as a factor that inhibits the proliferation of murine myeloid …
superfamily. Initially identified as a factor that inhibits the proliferation of murine myeloid …
Single-cell analysis of COVID-19, sepsis, and HIV infection reveals hyperinflammatory and immunosuppressive signatures in monocytes
The mortality risk of coronavirus disease 2019 (COVID-19) patients has been linked to the
cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
cytokine storm caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
Leukemia inhibitory factor, a double-edged sword with therapeutic implications in human diseases
Leukemia inhibitory factor (LIF) is a pleiotropic cytokine of the interleukin-6 (IL-6)
superfamily. LIF was initially discovered as a factor to induce the differentiation of myeloid …
superfamily. LIF was initially discovered as a factor to induce the differentiation of myeloid …
COVID‐19: A systematic review and update on prevention, diagnosis, and treatment
H Aghamirza Moghim Aliabadi… - MedComm, 2022 - Wiley Online Library
Since the rapid onset of the COVID‐19 or SARS‐CoV‐2 pandemic in the world in 2019,
extensive studies have been conducted to unveil the behavior and emission pattern of the …
extensive studies have been conducted to unveil the behavior and emission pattern of the …
Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients
Background Group 2 innate lymphoid cells (ILC2s) are effective producers of IL-5 and IL-13
during allergic inflammation and bridge the innate and adaptive immune responses. ILC2 …
during allergic inflammation and bridge the innate and adaptive immune responses. ILC2 …